Craft

Yumanity Therapeutics

Stock Price

$1.9

2022-12-19

Market Capitalization

$15.7 M

2022-12-19

Revenue

$5.4 M

FY, 2023

Yumanity Therapeutics Summary

Company Summary

Overview
Yumanity Therapeutics (formerly known as Proteostasis Therapeutics) is a biopharmaceutical company developing therapeutics to treat diseases caused by an imbalance in the proteostasis network. It specializes in the medicines for cystic fibrosis as well as treatments for the unfolded protein response dysfunction.
Type
Public
Status
Active
Founded
2014
HQ
Boston, MA, US | view all locations
Website
https://www.yumanity.com/
Cybersecurity rating
Sectors

Key People

  • David Arkowitz

    David Arkowitz, Director

    • Richard Peters

      Richard Peters, President, CEO, and Director

      • Kim Cobleigh Drapkin

        Kim Cobleigh Drapkin, Director

        • Devin Smith

          Devin Smith, SVP General Counsel

          LocationsView all

          1 location detected

          • Boston, MA HQ

            United States

            80 Guest St 5th floor

          Yumanity Therapeutics Financials

          Summary Financials

          Net income (Q1, 2025)
          ($1.6M)
          Cash (Q1, 2025)
          $304.0K
          EBIT (Q1, 2025)
          ($2.0M)
          Enterprise value
          $16.5M

          Footer menu